GOG-0283; A Phase II Trial of DCTD-Sponsored Dasatinib (NSC #732517 IND #120636) In Recurrent/Persistent Ovary Fallopian Tube Primary Peritoneal and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
This phase II trial studies how well dasatinib works in treating patients with persistent ovarian, fallopian tube, endometrial, or peritoneal cancer. Dasatinib may shrink patients' tumors by blocking some of the enzymes needed for cell growth.
Description
The purpose of this study is to test any good and bad effects of the study drug call Dasatnib on subjects with recurrent ovary, fallopian tube, primary peritoneal, and endometrial clear cell carcinoma.
Details
| Condition | ovarian cancer,fallopian tube cancer,endometrial cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX4417 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.